ATI RN
ATI Pathophysiology Exam
1. A male patient with benign prostatic hyperplasia (BPH) is prescribed finasteride (Proscar). What therapeutic effect is expected from this medication?
- A. Reduction in prostate size and improvement in urinary symptoms
- B. Increase in urine flow and relief of urinary obstruction
- C. Improvement in erectile function
- D. Relief of pain associated with BPH
Correct answer: A
Rationale: The correct answer is A: Reduction in prostate size and improvement in urinary symptoms. Finasteride works by reducing the size of the prostate gland, which in turn helps alleviate urinary symptoms such as frequency, urgency, weak stream, and incomplete emptying of the bladder. Choice B is incorrect as while finasteride can improve urine flow indirectly by reducing prostate size, it does not directly increase urine flow. Choice C is incorrect because finasteride is not intended to improve erectile function. Choice D is incorrect as finasteride does not primarily provide relief from pain associated with BPH.
2. A healthcare professional is assessing a client with suspected myasthenia gravis. Which symptom would the healthcare professional expect to find?
- A. Muscle atrophy
- B. Facial weakness
- C. Ptosis and diplopia
- D. Increased muscle tone
Correct answer: C
Rationale: Ptosis (drooping eyelid) and diplopia (double vision) are classic symptoms of myasthenia gravis. Muscle atrophy (Choice A) is not a typical early manifestation of myasthenia gravis. While facial weakness (Choice B) can occur, it is not as specific as ptosis and diplopia. Increased muscle tone (Choice D) is more indicative of conditions like spasticity, not myasthenia gravis.
3. What potential risk should the nurse identify as being associated with infliximab (Remicade) in the treatment of rheumatoid arthritis?
- A. Risk for infection
- B. Risk for decreased level of consciousness
- C. Risk for nephrotoxicity
- D. Risk for hepatotoxicity
Correct answer: A
Rationale: The correct answer is A: Risk for infection. Infliximab (Remicade) is a medication used to treat autoimmune conditions like rheumatoid arthritis. One of the main risks associated with infliximab is an increased susceptibility to infections due to its immunosuppressive effects. This drug works by targeting specific proteins in the body's immune system, which can weaken the body's ability to fight off infections. Choices B, C, and D are incorrect because infliximab is not typically associated with decreased level of consciousness, nephrotoxicity, or hepatotoxicity. It is important for healthcare providers to monitor patients on infliximab for signs of infection and educate them on the importance of infection prevention strategies.
4. When starting on oral contraceptives, what should the nurse include in the education regarding the timing of the medication?
- A. Oral contraceptives should be taken at the same time each day to maintain stable hormone levels and prevent pregnancy.
- B. Oral contraceptives can be taken at any time of day, as long as the schedule is consistent.
- C. Oral contraceptives should be taken in the morning to avoid nighttime side effects.
- D. Oral contraceptives are effective immediately upon starting, regardless of timing.
Correct answer: A
Rationale: When educating a patient starting on oral contraceptives, it is essential to stress the importance of taking the medication at the same time each day. This ensures stable hormone levels, improving the effectiveness of the contraceptives in preventing pregnancy. Choice B is incorrect because consistency in timing is crucial for maintaining hormone levels. Choice C is incorrect as there is no specific requirement to take oral contraceptives in the morning to avoid side effects. Choice D is incorrect as oral contraceptives may take some time to become fully effective, and consistent timing is important for their efficacy.
5. Women who have breast cancer due to a BRCA1 gene mutation are usually:
- A. positive for human epidermal growth factor receptor 1 and 2.
- B. negative for estrogen receptor.
- C. positive for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
- D. negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
Correct answer: D
Rationale: Women with breast cancer due to a BRCA1 gene mutation commonly have a triple-negative breast cancer subtype, which means they are negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). This subtype tends to be more aggressive and harder to treat. Choice A is incorrect as they are typically negative for HER2. Choice B is incorrect because they are usually negative for estrogen receptor. Choice C is incorrect as they are usually negative for progesterone receptor and HER2.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access